In this context, we have recently provided evidence that the capacity of a specific IGF1R antibody to block IGF1-mediated IGF1R activation was impaired in mutant BRCA1-expressing breast cancer cells [25]. This evidence concerns the gene IGF1R and breast carcinoma.